Interaction Checker
Potential Interaction
Dolutegravir/Rilpivirine (DTG/RPV)
Antacids
Quality of Evidence: Very Low
Summary:
Coadministration with dolutegravir/rilpivirine has not been studied. Coadministration of dolutegravir with polyvalent cation-containing products such as antacids may lead to decreased absorption of dolutegravir. Simultaneous coadministration of a magnesium/aluminium containing antacid (Maalox) and dolutegravir (50 mg once daily, n=16) decreased dolutegravir Cmax, AUC and Ctrough by 72%, 74% and 74%, respectively. When antacid was administered 2 hours after dolutegravir (50 mg once daily, n=16), dolutegravir Cmax, AUC and Ctrough decreased by 18%, 26% and 30%, respectively. The combination of rilpivirine and antacids should be used with caution as co-administration may cause significant decreases in rilpivirine plasma concentrations due to an increase in gastric pH. Antacids should be taken well separated in time from the administration of Juluca (minimum 6 hours before or 4 hours after).
Description:
View all available interactions with Dolutegravir/Rilpivirine (DTG/RPV) by clicking here.
No Version Present
Copyright © 2024 The University of Liverpool. All rights reserved.